{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560064,"version":"build-2803163510"},"reference-count":16,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2018,2,8]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the risk of significant adverse events in premature infants receiving the novel 4-component group B meningococcal vaccine (4CMenB) with their routine immunisations at 2\u2009months of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants, design and setting<\/jats:title>\n                  <jats:p>In December 2015, Public Health England requested neonatal units across England to voluntarily participate in a national audit; 19 units agreed to participate. Anonymised questionnaires were completed for infants receiving 4CMenB alongside their routine immunisations. For comparison, a historical cohort of premature infants receiving their primary immunisations without 4CMenB or paracetamol prophylaxis was used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Paracetamol use; temperature, cardiovascular, respiratory and neurological status before and after vaccination; and management and investigations postvaccination, including serum C reactive protein levels, infection screens and antibiotic use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Complete questionnaires were returned for 133 premature infants (&lt;35\u2009weeks\u2019 gestation) who received their first dose of 4CMenB at 8\u2009weeks of age, including 108 who received prophylactic paracetamol according to national recommendations. Overall, 7% (8\/108) of infants receiving 4CMenB with paracetamol had fever (&gt;38\u00b0C) after vaccination compared with 20% (5\/25) of those receiving 4CMenB without paracetamol (P=0.06) and none of those in the historical cohort. There were no significant differences between cohorts in the proportion of infants with apnoea, bradycardia, desaturation and receiving respiratory support after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>4CMenB does not increase the risk of serious adverse events in hospitalised premature infants. This audit supports the current national recommendations to offer 4CMenB with other routine vaccinations and prophylactic paracetamol to premature infants at their chronological age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/archdischild-2017-314152","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T12:23:20Z","timestamp":1523363000000},"page":"F171-F175","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Safety of meningococcal group B vaccination in hospitalised premature infants"],"prefix":"10.1136","volume":"104","author":[{"given":"Alison","family":"Kent","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim","family":"Beebeejaun","sequence":"additional","affiliation":[{"name":"Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Braccio","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, University of London, London, UK"},{"name":"Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seilesh","family":"Kadambari","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Croydon University Hospital, Croydon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Clarke","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK"},{"name":"Norwich Medical School, University of East Anglia, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T","family":"Heath","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, University of London, London, UK"},{"name":"Department of Paediatrics, St George\u2019s University Hospitals NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, University of London, London, UK"},{"name":"Department of Immunisation, Hepatitis and Blood Safety, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"2025090511155864000_104.2.F171.1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-308928"},{"key":"2025090511155864000_104.2.F171.2","first-page":"1","article-title":"Eff ectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England : a national observational cohort study","volume":"6736","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"2025090511155864000_104.2.F171.3","doi-asserted-by":"publisher","DOI":"10.1086\/656741"},{"key":"2025090511155864000_104.2.F171.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61961-8"},{"key":"2025090511155864000_104.2.F171.5","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28666"},{"key":"2025090511155864000_104.2.F171.6","unstructured":"Department of Health. Chapter 22: Meningococcal. In: Immunisation against infectious disease: Department of Health, 2016."},{"key":"2025090511155864000_104.2.F171.7","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313079"},{"key":"2025090511155864000_104.2.F171.8","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-312941"},{"key":"2025090511155864000_104.2.F171.9","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313419"},{"key":"2025090511155864000_104.2.F171.10","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-311020"},{"key":"2025090511155864000_104.2.F171.11","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2005.086306"},{"key":"2025090511155864000_104.2.F171.12","unstructured":"Department of Health. Contraindications and special considerations (Chapter 6). Immunisation against Infectious Disease: The Green Book, 2006. https:\/\/www.gov.uk\/government\/collections\/immunisation-against-infectious-disease-the-green-book."},{"key":"2025090511155864000_104.2.F171.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)80017-0"},{"key":"2025090511155864000_104.2.F171.14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3945","article-title":"Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT","volume":"138","author":"Kent","year":"2016","journal-title":"Pediatrics"},{"key":"2025090511155864000_104.2.F171.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.85"},{"key":"2025090511155864000_104.2.F171.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.02.059"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2017-314152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:40:43Z","timestamp":1757097643000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2017-314152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,19]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/archdischild-2017-314152"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2017-314152","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]}}}